Jakob Werner Hansen: Nordic VEX AZA Trial Reaches an Important Milestone
Jakob Werner Hansen, PhD at Rigshospitalet, shared a post on LinkedIn:
“We have reached an important milestone!
The last patient has now been included in our Nordic VEX AZA trial, where we are investigating azacitidine as a treatment for patients with VEXAS syndrome. The first prospective trial in the world to explore this.
We will present our pre-planned interim analysis in the near future, followed by the full analysis in 2027, when the last patient has been evaluated for the primary endpoint: reduction in UBA1 variant allele frequency.
The study is a truly pan Nordic collaboration, involving centres across Finland, Sweden, Norway, and Denmark with patients included from all four countries. It has been an incredible collaborative effort!
A huge thank you to all the patients participating in the trial, and to all the participating centres, physicians, nurses, monitors, and laboratory teams who have contributed to making this study possible.
Our trial office is small but truly amazing Markus Korsholm Kristensen and Sune Bengtsen Holm Hansen!
The next arm of the study is opening this week!
Thank you to the Danish Cancer Society (Kræftens Bekæmpelse) and the Novo Nordisk Foundation for supporting and enabling this study.
I have many lovely collaborators to thank, without the support it had never been possible money are small in investigator initiated trials but good people makes it possible.
P.S Our Nordic logo was created by the very first patient I enrolled in our trial a personal touch.
RigshospitaletNovo Nordisk FoundationKræftens Bekæmpelse (Danish Cancer Society)
Next stop 3rd international VEXAS workshop.”
Stay updated with Hemostasis Today.
-
Sep 16, 2026, 09:20Mengistu Abate Belay: Bridging the Gap in Anemia Prevention During Pregnancy
-
Sep 16, 2026, 09:09Younes Kalakhy: When Normal Coagulation Tests Miss von Willebrand Disease
-
Sep 16, 2026, 09:00Test Your Knowledge of Warm Autoimmune Hemolytic Anemia – ASH Education
-
Sep 16, 2026, 08:28Jean Nakhle: Uncovering How Excess Cysteine Drives Cell Death
-
Sep 16, 2026, 08:20Heghine Khachatryan: Arterial and Venous Thrombosis May Require Different Approaches in Neonates
-
Sep 16, 2026, 07:57Tammuella Chrisentery-Singleton: Standing on the Shoulders of Giants in Hemophilia Care
-
Sep 16, 2026, 06:54Jonathan Furniss: The Platelet Response That Helps Drive Tissue Repair
-
Sep 16, 2026, 05:25Paul Armstrong: Honoured to Take the Lead at The Platelet Society
-
Sep 16, 2026, 05:05Alejandro González Veliz: Why Heart Attacks in Women Can Be More Complex Than a Simple Blockage